Fortress Biotech Inc (FBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Fortress Biotech Inc stock (FBIO) is currently trading at $2.99. Fortress Biotech Inc PS ratio (Price-to-Sales) is 1.57. Analyst consensus price target for FBIO is $10.75. WallStSmart rates FBIO as Sell.
- FBIO PE ratio analysis and historical PE chart
- FBIO PS ratio (Price-to-Sales) history and trend
- FBIO intrinsic value — DCF, Graham Number, EPV models
- FBIO stock price prediction 2025 2026 2027 2028 2029 2030
- FBIO fair value vs current price
- FBIO insider transactions and insider buying
- Is FBIO undervalued or overvalued?
- Fortress Biotech Inc financial analysis — revenue, earnings, cash flow
- FBIO Piotroski F-Score and Altman Z-Score
- FBIO analyst price target and Smart Rating
Fortress Biotech Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Fortress Biotech Inc (FBIO) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
Fortress Biotech Inc (FBIO) Key Strengths (3)
Paying $1.57 for every $1 of annual revenue
Trading at 1.77x book value, attractively priced
Strong revenue growth at 20.50% annually
Supporting Valuation Data
Fortress Biotech Inc (FBIO) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Thin profit margins with limited profitability
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Fortress Biotech Inc (FBIO) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (1.57), Price/Book (1.77) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 20.50%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -205.30%, Operating Margin at -38.60%, Profit Margin at 6.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -205.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 20.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FBIO's Price-to-Sales ratio of 1.57x trades at a deep discount to its historical average of 11.95x (49th percentile). The current valuation is 99% below its historical high of 125.52x set in Apr 2016, and 1212% above its historical low of 0.12x in Sep 2023. Over the past 12 months, the PS ratio has expanded from ~0.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Fortress Biotech Inc (FBIO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Fortress Biotech Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 62M with 21% growth year-over-year. Profit margins are thin at 6.4%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Fortress Biotech Inc push profit margins above 15% as the business scales?
Growth sustainability: can Fortress Biotech Inc maintain 21%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Fortress Biotech Inc.
Bottom Line
Fortress Biotech Inc offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(9 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:35:49 AM
About Fortress Biotech Inc(FBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.